SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Tuesday, February 5, 2008 at 4:00 pm Eastern Time (1:00 pm Pacific Time) during the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcasts and will be archived for 14 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,
Contacts: William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved